Fate Therapeutics
Last updated: November 23, 2025
Scott Wolchko - President & CEO
Country: USA | Funding: $1.3B (+)
Founded: 2007
Website: http://www.fatetherapeutics.com/
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Founded: 2007
Website: http://www.fatetherapeutics.com/
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
